Alpha-interferon and oral fluorouracil in the treatment of unremovable and/or metastatic renal cancer.
We present the results obtained in a study of the pharmacological action (phase II) of alpha-interferon and oral fluorouracyl administered in our 2-year study (Feb. 1988-Feb. 1990) in 10 patients suffering from surgically unremovable or metastatic renal cancer. Our results were: 1 patient with complete regression of lung metastasis; 5 with progressive disease within 3-4 months from beginning of treatment and 2 deaths with stable disease after 4-5 months. Two patients abandoned treatment and their disease progressed within 4-5 months.
Romero
J A
JA
Department of Urology, Hospital Clinic, University of Barcelona, Spain.
Alvarez-Vijande
R
R
Gil-Vernet
J M
JM
Samsón
R
R
Fernández
I
I
Gutiérrez
R
R
Carretero
P
P
D000328:Adult; D000368:Aged; D001859:Bone Neoplasms / Q000556:secondary; D003131:Combined Modality Therapy; D005260:Female; D005472:Fluorouracil / Q000008:administration & dosage* / Q000009:adverse effects; D006801:Humans; D016898:Interferon-alpha / Q000008:administration & dosage* / Q000009:adverse effects; D007680:Kidney Neoplasms / Q000473:pathology / Q000628:therapy*; D008113:Liver Neoplasms / Q000556:secondary; D008175:Lung Neoplasms / Q000556:secondary; D008297:Male; D008875:Middle Aged
D016898:Interferon-alpha; D005472:Fluorouracil